Investors hope Natus Medical
What analysts say:
- Buy, sell, or hold?: Analysts strongly back Natus Medical, with seven of nine rating it a buy and the remainder rating it a hold. Analysts like Natus Medical better than competitor CONMED overall. Analysts still rate the stock a Moderate buy, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $57.9 million in revenue this quarter. That would represent a rise of 9.9% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate calls for earnings of $0.14 per share. Estimates range from $0.12 to $0.18 per share.
What our community says:
CAPS All Stars are solidly behind the stock, with 98.2% granting it an "outperform" rating. The community at large backs the All Stars, with 97.5% giving it a rating of "outperform." Fools are keen on Natus Medical and haven't been shy with their opinions lately, logging 317 posts in the past 30 days. Even with a robust four out of five stars, Natus Medical's CAPS rating falls a little short of the community's upbeat outlook.
Management:Now let's look at how efficient management is at running the business. Traditionally, margins represent the efficiency with which companies capture portions of sales dollars. The following table shows gross, operating, and net margins over the past four quarters.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Natus Medical now.
Motley Fool newsletter services have recommended buying shares of Natus Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.